INVA Q4 2017 Earnings Call Summary | Stock Taper
Logo
Pricing Log In
INVA

INVA — Innoviva, Inc.

NASDAQ

Q4 2017 Earnings Call Summary

February 8, 2018

Summary of Innoviva (INVA) Q4 2017 Earnings Call

1. Key Financial Results and Metrics

  • Q4 2017 Net Sales:
    • RELVAR/BREO: $405.3 million (up 48% YoY)
    • ANORO: $147.3 million (up 62% YoY)
    • TRELEGY ELLIPTA: $2.8 million (launched in Q4)
  • Royalties for Q4 2017: $70.5 million (up 51% YoY), including $60.8 million from BREO and $9.5 million from ANORO.
  • Income from Operations: $66.4 million (up 76% YoY).
  • Adjusted EBITDA: $72.3 million (up 65% YoY), with a margin of 91%.
  • Net Income: $58.4 million or $0.50 EPS (up 129% YoY).
  • Full Year 2017: Total royalties earned were $227.9 million, with an adjusted EBITDA of $207.5 million.

2. Strategic Updates and Business Highlights

  • Innoviva reported record high TRx market shares for BREO (19.5%) and ANORO (16%) in the U.S.
  • Strong prescription volume growth: BREO grew 77% YoY, and ANORO grew 69% YoY compared to respective market growths of 4%.
  • The launch of TRELEGY ELLIPTA is seen as a strategic addition to the portfolio, allowing for a progression of treatments using the same device.
  • The company emphasized the importance of its partnership with GSK to maximize the potential of its respiratory products.

3. Forward Guidance and Outlook

  • Innoviva remains optimistic about its prospects in 2018, focusing on the commercial success and global rollout of its products.
  • The company expects a positive impact from U.S. tax reform, anticipating lower cash taxes due to the reduction in the corporate tax rate from 35% to 21%.
  • Continued strong cash flow generation and reduced debt levels position Innoviva favorably for future growth.

4. Bad News, Challenges, or Points of Concern

  • Despite strong performance, there are concerns regarding competitive pressures affecting market share dynamics, particularly for BREO, which saw flat new-to-brand market share during Q4.
  • The company faced costs related to a proxy contest, which impacted EPS by approximately $0.08 for the year.
  • The need for couponing in a mature and competitive respiratory market remains a challenge, although coverage for BREO and ANORO is reported to be strong.

5. Notable Q&A Insights

  • The D&O insurance recovery discussed in Q&A was related to prior quarter litigation costs.
  • Eric d'Esparbes indicated that couponing is an essential tool for GSK in the commercialization of their products, although its necessity is decreasing as coverage improves.
  • Initial feedback for TRELEGY was too early to assess definitively, but there is optimism regarding its market uptake given the existing demand for triple therapy in COPD treatment.

Overall, Innoviva reported a strong financial performance in Q4 2017, with significant growth in sales and profitability, while also navigating competitive pressures and strategic challenges in the respiratory market.